U.S. markets close in 2 hours 23 minutes
  • S&P 500

    3,901.11
    -0.71 (-0.02%)
     
  • Dow 30

    31,588.98
    +53.47 (+0.17%)
     
  • Nasdaq

    13,501.87
    -86.96 (-0.64%)
     
  • Russell 2000

    2,248.96
    -26.36 (-1.16%)
     
  • Crude Oil

    60.71
    +0.07 (+0.12%)
     
  • Gold

    1,734.50
    +11.50 (+0.67%)
     
  • Silver

    26.88
    +0.20 (+0.74%)
     
  • EUR/USD

    1.2092
    +0.0032 (+0.27%)
     
  • 10-Yr Bond

    1.4220
    -0.0240 (-1.66%)
     
  • GBP/USD

    1.3973
    +0.0052 (+0.38%)
     
  • USD/JPY

    106.7490
    +0.0190 (+0.02%)
     
  • BTC-USD

    47,881.59
    -1,113.19 (-2.27%)
     
  • CMC Crypto 200

    960.19
    -26.46 (-2.68%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Kala Pharmaceuticals to Present at BofA Securities 2020 Health Care Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the virtual BofA Securities 2020 Health Care Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, May 13th, 2020 at 4:20 p.m. ET.

To access a live webcast and subsequent archived recording of the presentation, please visit the "Investors & Media" section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFYTM mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, which is being studied for the short-term treatment of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200506005011/en/

Contacts

Investor Contact:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200